The autotaxin-lysophosphatidic acid pathway emerges as a therapeutic target to prevent liver cancer

Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals,...

Descripción completa

Detalles Bibliográficos
Autores principales: Erstad, Derek J., Tager, Andrew M., Hoshida, Yujin, Fuchs, Bryan C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2017
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5462520/
https://www.ncbi.nlm.nih.gov/pubmed/28616586
http://dx.doi.org/10.1080/23723556.2017.1311827
Descripción
Sumario:Using transcriptome meta-analysis, we recently identified the autotaxin (ATX)-lysophosphatidic acid (LPA) pathway as a regulator of hepatocellular carcinoma (HCC) risk in human cirrhosis patients. Pharmacological targeting of this pathway reduced fibrosis progression and HCC development in animals, identifying ATX-LPA signaling as a novel chemoprevention strategy for cirrhosis and HCC.

Ejemplares similares